Journal of Clinical Oncology, Vol 16, 914-919, Copyright © 1998 by American Society of Clinical Oncology
Feasibility, toxicity, and biologic response of interleukin-2 after consolidation chemotherapy for acute myelogenous leukemia: a report from the Children's Cancer Group
EL Sievers, BJ Lange, PM Sondel, MD Krailo, J Gan, W Liu-Mares and SA Feig
Division of Pediatric Oncology, Fred Hutchinson Cancer Research Center, Seattle, WA, USA. esievers@fhcrc.org
PURPOSE: Although remission can be achieved in 80% of children with acute
myelogenous leukemia (AML), many patients experience relapse. Because
interleukin-2 (IL-2) can induce remission in patients with overt evidence
of AML, we hypothesized that IL-2 given to patients in first remission
after intensive consolidation chemotherapy might prevent relapse. This
study sought to determine whether such an approach was feasible. PATIENTS
AND METHODS: Twenty-one patients in complete remission received IL-2 after
completion of treatment on Children's Cancer Group (CCG) protocol 2941.
Recombinant IL-2 9 x 10(6) IU/m2 daily by continuous intravenous infusion
(c.i.v.) was given for 4 days. After 4 days rest, IL-2 1.6 x 10(6) IU/m2
daily c.i.v. was resumed for 10 days. We monitored patients for toxicity
and measured absolute lymphocyte count, the absolute count of cells that
express CD56 and CD3 antigen, and soluble IL-2 receptor alpha-chain (sIL-2R
alpha) levels before the start of IL-2 and after completion of each of the
two courses of IL-2. RESULTS: Observed toxicities included fever (57%),
vascular leak (48%), hypotension (38%), tachycardia (14%), rash (29%),
septicemia (5%), thrombocytopenia (29%), elevated transaminase (14%),
electrolyte disturbance (29%), and hyperglycemia (10%). No patient required
cardiac pressors or transfer to an intensive care unit. All patients
studied developed an increase in lymphocyte count, CD56 count, CD3 count,
and sIL-2R alpha levels after treatment with IL- 2. CONCLUSION: This
schedule of IL-2 was reasonably well tolerated by children with AML in
first remission. After treatment, increased levels of sIL-2R alpha were
observed. CCG is conducting a randomized prospective trial to assess the
efficacy of IL-2 to prevent the relapse of AML (CCG-2961).
 CiteULike  Complore  Connotea  Del.icio.us  Digg  Facebook  Reddit  Technorati  Twitter What's this?
This article has been cited by other articles:
|
|
|
|
 
B. J. Lange, F. O. Smith, J. Feusner, D. R. Barnard, P. Dinndorf, S. Feig, N. A. Heerema, C. Arndt, R. J. Arceci, N. Seibel, et al.
Outcomes in CCG-2961, a Children's Oncology Group Phase 3 Trial for untreated pediatric acute myeloid leukemia: a report from the Children's Oncology Group
Blood,
February 1, 2008;
111(3):
1044 - 1053.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
W. Schwinger, V. Klass, M. Benesch, H. Lackner, H. J. Dornbusch, P. Sovinz, A. Moser, G. Schwantzer, and C. Urban
Feasibility of high-dose interleukin-2 in heavily pretreated pediatric cancer patients
Ann. Onc.,
July 1, 2005;
16(7):
1199 - 1206.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Brown, S. Meshinchi, M. Levis, T. A. Alonzo, R. Gerbing, B. Lange, R. Arceci, and D. Small
Pediatric AML primary samples with FLT3/ITD mutations are preferentially killed by FLT3 inhibition
Blood,
September 15, 2004;
104(6):
1841 - 1849.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. T.H. Yeh, A. T. Tong, D. J. Lenihan, S. W. Yusuf, J. Swafford, C. Champion, J.-B. Durand, H. Gibbs, A. A. Zafarmand, and M. S. Ewer
Cardiovascular Complications of Cancer Therapy: Diagnosis, Pathogenesis, and Management
Circulation,
June 29, 2004;
109(25):
3122 - 3131.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. J. Lange, P. Dinndorf, F. O. Smith, C. Arndt, D. Barnard, S. Feig, J. Feusner, N. Seibel, M. Weiman, R. Aplenc, et al.
Pilot Study of Idarubicin-Based Intensive-Timing Induction Therapy for Children With Previously Untreated Acute Myeloid Leukemia: Children's Cancer Group Study 2941
J. Clin. Oncol.,
January 1, 2004;
22(1):
150 - 156.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
